Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults

for the IMPAACT P1058A Team

Research output: Contribution to journalArticle

Abstract

Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.

Original languageEnglish (US)
Pages (from-to)294-296
Number of pages3
JournalJournal of the Pediatric Infectious Diseases Society
Volume6
Issue number3
DOIs
StatePublished - Sep 1 2017

Keywords

  • Antiretrovirals
  • Darunavir
  • Etravirine
  • Pediatrics
  • Ritonavir

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults'. Together they form a unique fingerprint.

  • Cite this